Insulet Corporation (PODD)
Makes wearable insulin pumps that automatically dose diabetes patients throughout the day.
$167.99+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-40.5%
The outlook
Insulet has strong analyst backing with a consensus "Strong Buy" rating, and the average price target sits roughly 42% above the current price. The stock is trading near its 52-week low and showing mixed momentum against its moving averages. The overall assessment is neutral, reflecting the gap between bullish analyst views and the stock's currently depressed technical position.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 23 analysts
Price trendMixed vs its moving averages
52-week range14% of the way from its 52-week low to high
Price targetAvg target +42% vs current price
Analyst price target
~12-month · 23 analysts$238.22average target+41.8% vs now
Now $167.99
Low $172.00High $360.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$11.64B
52-wk high
$354.88
52-wk low
$138.79
50-day avg
$154.01
200-day avg
$235.13
Trailing P/E
39.3